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Abstract 
Fosfomycin (FOS) is a natural bactericidal broad-spectrum antibiotic which acts on proliferating bacteria by 
inhibiting cell wall and early murein/peptidoglycan synthesis. Bactericidal activity is evident against Gram positive 
and Gram negative bacteria and can also act synergistically with other antibiotics. Bacterial resistance to FOS may 
be natural or acquired. Other properties of this drug include inhibition of bacterial adhesion to epithelial cells, 
exopolysaccharide biofilm penetration, immunomodulatory effect, phagocytosis promotion and protection against 
the nephrotoxicity caused by other drugs. FOS has chemical characteristics not typically observed in organic 
phosphoric compounds and its molecular weight is almost the lowest of all the antimicrobials. It tends to form salts 
easily due to its acidic nature (disodium salt, for intravenous (IV), intramuscular (IM) and subcutaneous (SC) 
administration; calcium and trometamol salt: for oral (PO) administration). FOS has a very low protein binding 
(<0.5%) which, along with its low molecular weight and water solubility, contributes to its good diffusion into fluids 
(cerebrospinal fluid, aqueous and vitreous humor, interstitial fluid) and tissues (placenta, bone, muscle, liver, kidney 
and skin/fat). In all species, important differences in the bioavailability have been found after administration in 
relation to the various derivatives of FOS salts. Pharmacokinetic profiles have been described in humans, chickens, 
rabbits, cows, dogs, horses and weaning piglets. The low toxicity and potential efficacy of FOS are the main factors 
that contribute to its use in humans and animals. Thus, it has been used to treat a broad variety of bacterial infections 
in humans, such as localized peritonitis, brain abscesses, severe soft tissue infections, cystitis and other conditions. 
In veterinary medicine, FOS is used to treat infectious diseases of broiler chickens and pigs. In broilers, it is 
administered for the treatment of E. coli and Salmonella spp. infections. In piglets, the drug is prescribed to treat a 
wide variety of bacterial infections. FOS penetration is demonstrated in phagocytic, respiratory (HEP-2) and 
intestinal (IPEC-J2) cells. Although not widely used in animals, the drug has shown good results in human 
medicine. The potentialities of FOS suggest that this drug is a promising candidate for the treatment of infections in 
veterinary medicine. For these reasons, the aim of this work is to provide animal health practitioners with 
information on a drug that is not extensively recognized.  
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Introduction 
Fosfomycin (FOS) (cis-1,2-epoxyphosphonic acid), 
initially known as ‘phosphonomycin’ (Hendlin et al., 
1969), is a natural bactericidal broad-spectrum 
antibiotic that is not structurally related to other 
classes of antimicrobial agents (Escolar Jurado et al., 
1998; Popovic et al., 2010).  
It was isolated in 1966 from a Streptomyces fradiae 
strain, obtained from a soil sample, and later, from 
Streptomyces viridochromogenes, Streptomyces 
wedmorensis (Hendlin et al., 1969; Grassi, 1990), 
Pseudomona viridiflava and Penicillum strains 
(Hidaka et al., 1992; Hidaka et al., 1995; Shi et al., 
2001). Currently, it is exclusively produced by 
chemical synthesis (Gobernado, 2003). 
FOS is a Spanish antibiotic, undervalued in the 
English medical literature and not regularly used in its 
country of origin (Vargas et al., 1987; Gudiol, 2007). 
FOS is being used in veterinary medicine for over 40 
years. However, it is usually considered a second line 
antibiotic (Vargas et al., 1987), mainly due to the lack 
of knowledge among veterinary professionals. This 
unrecognition of the drug reflects the fact that most of 
the studies are performed in humans and they are 
scarce and only recently applied to domestic animal 
medicine. Nevertheless, FOS is a good antibiotic, with 
a fast effect, good tolerance (Ilender, 1998) and 
physicochemical and pharmacokinetic characteristics 
that allow its enteral and parenteral administration 
(Dámaso et al., 1990; Mensa et al., 1994). 
FOS has a very low protein binding (<0.5%). Thus, it 
has good diffusion in corporal tissues, interstitial and 
intracellular fluids, coming through the blood brain 
barrier into the amniotic fluid, aqueous humor, lymph 
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tissue, purulent bronchial secretions and fluids 
(Gobernado, 2003). In pharmacokinetics studies, due 
to the almost undetectable protein binding, the 
obtained plasma values represent almost all FOS 
available at a given moment (Zozaya et al., 2008). 
FOS has been shown to exert a time dependant 
microbial growth inhibition (Sauermann et al., 2005). 
Thus, it has been speculated that its optimal 
bactericidal effect can be obtained at three to four 
times the concentration that inhibits 90% (MIC90) of 
bacterial isolates (Pfausler, 2004) and not necessarily 
linked to high maximum plasma concentration (Cmax) 
values (McKellar et al., 2004).  
Mazzei et al. (2006) have also described a 
postantibiotic effect (PAE) of 3.4-4.7 h. It is important 
to note that drugs acting by concentration peak 
(Cmax/MIC) and antimicrobial dependent AUC/MIC 
concentration have higher PAE, such as 
aminoglycosides and ciprofloxacin which have PAE 
of 2 to 6 h in Gram negatives. The b-lactams do not 
have PAE in Gram negatives and it is only 2 h in 
Gram positives. Then, considering the PAE of other 
drugs, FOS can be considered to have a significant 
PAE (Labarca, 2002).  
Chemical structure  
FOS is a propionic acid derivative which corresponds 
to the formula of an epoxide. The simple water-
soluble molecule is similar to phosphoenolpyruvate 
(PEP). It has only three carbon atoms and no nitrogen. 
The antibacterial activity is due to the epoxy bond 
(Gobernado, 2003). 
The molecule has a number of chemical characteristics 
which are not typically observed in organo 
phosphorous compounds. On one hand, it is formed by 
an epoxy group to which the negatively charged 
phosphoric group binds and which is decisive for its 
antibacterial action. On the other hand, it presents a 
direct bond between the carbon and phosphorus 
without an oxygen intermediate bridge, as is usual in 
organo phosphorus compounds (Baron and Drugeon, 
1985) (Fig. 1). Its molecular weight is almost the 
lowest of all the antimicrobials (138 '1) (Moritz, 1986; 
Neuman, l990; Gutiérrez et al., 2008), which added to 
its low protein binding, favors the spread of the drug 
to tissues and fluids. 
 
Fig. 1. Fosfomycin chemical structure. 
 
FOS tends to form salts easily due to its acidic nature. 
Its chemical structure is presented in different salts: 
disodium salt is used for IV and SC administration, 
while trometamol salt (tromethamine 
[trihydroxymethyl aminomethane]) and the calcium 
salt are used for oral administration (Escolar Jurado et 
al., 1998). Disodium and calcium salts, which are 
parenterally and orally used, respectively, are obtained 
by substituting the two hydrogen atoms of the 
phosphoric radical by two atoms of sodium and one of 
calcium.  
Trometamol salt, available since 1990 (Gudiol, 2007) 
and commercially available for oral use, is obtained by 
adding a molecule of tromethamine to the phosphoric 
radical. Tromethamine (tris-hydroxymethyl-
aminomethane) is a synthetic buffer for short term use 
(Gomis et al., 1992), which leads to a molecular 
weight of FOS that is nearly the double of the original 
drug, without contributing or interfering with its 
antibacterial action. Figure 2 shows FOS different 
salts. 
 
 
Fig. 2. Fosfomycin different salts. (A): Disodium FOS, (B): 
Calcium FOS and (C): Trometamine FOS. Chemicals 
properties make FOS a peculiar antibiotic and substitutions 
of its H atoms by other radicals (Na+1 or Ca+2) gives rise to 
the different salts. 
 
Spectrum of action 
FOS has bactericidal activity against Gram positive 
and Gram negative bacteria (Mata et al., 1977; 
Gobernado, 2003) and when compared to penicillins 
and semi-synthetic cephalosporins, it has a broader 
spectrum of action (Mata et al., 1977). 
FOS bactericidal effect is fast which has been 
demonstrated by laboratory assays, such as turbidity 
reduction in liquid culture media and colony reduction 
on solid media passes (Rodicio et al., 1978; Schmid, 
1979; Schmid, 1980; Carlone et al., 1982; Schmid, 
1985). Minimum inhibitory concentration (MIC) and 
Minimum bactericidal concentration (MBC) values 
are similar to the majority of gram-positive and gram-
negative bacteria, being lower when incubated under 
anaerobic conditions, probably reflecting a lower FOS 
transport through the cell membrane under these 
conditions (Inouye et al., 1989; Hamilton-Miller, 
1992).  
In intensive productions (poultry and swine 
production), FOS is used for the treatment of 
infections caused by sensitive Gram positives and 
Gram negatives germs, such as Salmonella sp., 
Escherichia coli, Pasteurella sp., Staphylococcus sp., 
Streptococcus sp., Haemophilus sp., Klebsiella sp. 
(good activity) and Pseudomona sp. (moderate 
activity). Its activity against Listeria, Leptospira, 
Clostridium spp. and Vibrio spp. is moderate. It is not 
active against bacteroids (García-Rodríguez, 1984), 
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Mycobacterium spp., Leggionella spp., Borrelia spp., 
and, naturally, against bacteria without cell wall such 
as Coxiella burnetii, Rickettsia, Chlamydia, 
Mycoplasma and Ureaplasma, which are insensible to 
FOS.  
FOS spectrum of action is shown in Table 1. MICs for 
microorganisms most commonly found in animals, for 
which FOS was used in their treatment are in the 
range of 0.25-0.5 g/mL (Fernández et al., 1995) 
(Streptococcus spp., S. aureus, Enterococcus sp., E. 
coli, among others).  
Note that these microorganisms are in the first column 
of Table 1 that represents species for which FOS has a 
good in vitro activity. FOS has a fast bactericidal 
effect against a broad spectrum of animal and human 
pathogens. 
Mechanism of action 
FOS penetrates bacteria by two systems of permeases, 
one that transports L α glycerol phosphate, and other, 
which is inducible and takes D-glucose-6-phosphate 
inside the bacterial cytoplasm (Popovic et al., 2010). 
FOS acts in proliferating bacteria by inhibition of cell 
wall and early murein/peptidoglycan synthesis (Kahan 
et al., 1974).  
It inhibits an initial step in peptidoglycan synthesis 
(Mensa et al., 1994), which is triggered by an analog 
of FOS (Kahan et al., 1974; Popovic et al., 2010), 
uridine diphosphate N-acetyl-glucosamine-enol-
pyruvyl-transferase and its co-enzyme, phosphoenol-
pyruvate (PEP).  
FOS acts on bacteria in the growth phase without 
interfering with the reactions requiring PEP in animal 
cells. This is because, in animals, enzymatic attack 
occurs at a different place from PEP and the enzyme 
does not recognize FOS as a substrate. FOS inhibits 
the binding of PEP to N-acetylglucosamine. For wall 
synthesis, the group-O-PO3H2 of PEP is separated, 
binding the pyruvate C2 to the oxygen of an N-
acetylglucosamine.  
However, in eukaryotic cells, the oxygen remains 
attached to C2, separating only the phosphate PO3H2. 
FOS has in its molecule the -OCP-sequence, which is 
different from the -COP sequence of PEP. This fact 
explains the high selectivity of FOS, which inhibits 
the use of PEP in the cell wall synthesis (where the 
enzyme cleaves OL binding) and not in the 
metabolism of eukaryotic cells (where enzymes break 
the union OP). Figure 3 shows FOS mechanism of 
action. 
FOS inhibits cell wall synthesis due to its analogy 
with uridine diphosphate N-acetyl-glucosamine-enol-
pyruvyl-transferase. PEP is the coenzime of the 
reaction. However, FOS does not interfere with the 
reactions requiring PEP in animal cells. In animals, 
enzymatic attack occurs at a different place from PEP 
and the enzyme does not recognize FOS as a substrate. 
 
Fig. 3. FOS (F) is transported inside the cell by glycerol-3-
phosphate transporter (GlpT) and glucose-6-phosphate 
transporter (UhpT) blocking the UDP-GlcNac-3-O-
enolpyruvate synthesis by mimicking the original substrate 
of UDP-GlcNAc enolpyruvyl transferase (MurA), 
phosphoenolpyruvate (PEP), and in the process avoiding cell 
wall synthesis and leading to cell death. 
 
EFFECT OF THE ASSOCIATION WITH OTHER 
ANTIBIOTICS 
Due to its mechanism of action in the first steps of cell 
wall production, FOS can act synergistically with 
other antibiotics, especially those which inhibit the 
late stages in the cell wall synthesis (Gudiol, 2007). It 
shows a synergistic partnership with other 
antimicrobials, mainly, with beta-lactams, 
aminoglycosides, chloramphenicol, tetracycline, 
erythromycin, cotrimoxazole and quinolones (Salhi et 
al., 1986; Damaso et al., 1990; Ilender, 1998).  
In association with penicillin it has a synergistic effect 
on S. aureus and S. pneumoniae, with ampicillin it is 
synergic on S. aureus and E. coli and with 
cephalosporins, it has synergistic effect on S. aureus 
and P. aeruginosa. Furthermore, synergism with 
vancomicin has been demonstrated on S. aureus and S. 
epidermidis, with imipenem on S. epidermidis and K. 
pneumoniae, with rifampicin on S. epidermidis and E. 
faecalis, with ciprofloxacin, on S. aureus, S. 
epidermidis and E. faecalis with streptomycin it is 
synergic on E. coli and has a synergistic-additive 
effect on S. aureus, and P. aeruginosa (Gobernado, 
2003). Table 2 shows FOS synergistic partnership 
with other antimicrobials. 
FOS acts synergistically with antibiotics which inhibit 
the late stages of cell wall synthesis. The pathogens 
mainly affected by this synergistic effect are S. 
aureus, S. epidermidis, K. pneumoniae, P. aeruginosa 
and E. coli. 
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Table 1. Fosfomycin spectrum of action. 
 
 Good Activity 
MIC < 16 mL/L 
Moderate Activity 
MIC < 16-64 mL/L 
Without Activity 
MIC < 64 mL/L 
Aerobic Gram-positive 
bacteria 
Staphylococcus aureus 
Staphylococcus epidermidis 
Streptococcus pyogenes 
Streptococcus viridans 
Streptococcus pneumoniae 
Streptococcus (groups C-F-G) 
Enterococcus faecalis 
Enterococcus faecium 
Staphylococcus haemolyticus 
Staphylococcus agalactiae 
Listeria monocytogenes 
Other Staphilococcus spp. 
Mycobacterium spp. 
Nocardia sp. 
 
Aerobic Gram negative 
bacteria 
- - 
Moraxella spp. 
Bordetella spp. 
Legionella spp. 
Facultative aerobic - 
anaerobic Gram-negative 
bacteria 
Histophilus somni  
Escherichia coli  
Klebsiella pneumoniae  
Serratia spp.  
Citrobacter spp.  
Proteus mirabilis  
Proteus vulgaris  
Salmonella spp.  
Shigella spp. 
Aeromonas spp. 
Yersinia enterocolitica 
 
Corynebacterium spp. 
Brucella spp. 
 
Microaerophilic bacteria Campylobacter jejuni   
Anaerobic Gram-negative 
bacteria 
Peptococcus spp. 
Fusobacterium spp. 
 
Mycobacterium spp. 
Bacteroides 
Gram-negative, without cell 
wall 
  
Coxiella burnetti (Ae) 
Rickettsia spp. (Ae) 
Chlamydia spp. (Ae) 
Mycoplasma spp. (FAA) 
Ureaplasma spp. (FAA) 
A= Aerobic 
FAA = Facultative aerobic anaerobic 
 
Table 2. Effect of Fosfomycin in association with other 
antibiotics. 
 
FOS associated 
with 
Microorganism Effect 
Penicillin 
Staphylococcus aureus 
Staphylococcus pneumoniae 
Synergistic 
Ampicillin 
Staphylococcus aureus 
Escherichia coli 
Synergistic 
Cephalosporins 
Staphylococcus aureus 
Pseudomonas aeruginosa 
Synergistic 
Vancomicin 
Staphylococcus aureus 
Staphylococcus epidermidis 
Synergistic 
Imipenem 
Staphylococcus epidermidis 
Klebsiella pneumoniae  
Synergistic 
Rifampicin 
Staphylococcus epidermidis 
Enterococcus faecalis 
Synergistic 
Ciprofloxacin 
Staphylococcus aureus 
Staphylococcus epidermidis 
Enterococcus faecalis 
Synergistic 
Streptomycin Escherichia coli Synergistic 
Streptomycin 
Staphylococcus aureus 
Pseudomonas aeruginosa 
Synergistic
-Additive 
 
RESISTANCE 
Bacterial resistance to FOS has been related to 
transport alteration through cell wall, target alteration 
and, rarely, to enzymatic breakage (Gobernado, 2003). 
Besides this natural resistance, acquired resistance 
associated with transport or chromosomic alterations 
has also been reported (Damaso et al., 1990). 
Extrachromosomal resistance, governed by plasmids, 
has also been described (Obaseiki-Ebor, 1986; Villar 
et al., 1986). Castañeda-García et al. (2013) considers 
three different possible mechanisms leading to FOS 
resistance: a) reduced permeability to FOS, b) 
modification of the antibiotic target MurA (UDP-
GlcNAc enolpyruvyl transferase), c) antibiotic 
modification.  
Chromosomal resistance is manifested by the 
production of the enzyme FOS glutathione S-
transferase, which inactivates the antibiotic by 
producing a bond between glutathione and FOS (Arca 
et al., 1990). The enzyme is located in the periplasmic 
space. This kind of resistance has been described in 
both gram-positive and gram-negative bacteria 
(Venkateswaran and Wu, 1972; Kurashige et al., 
1975; Cordaro et al., 1976; Gershanovich et al., 1980; 
Hardisson et al., 1984; Mlynarczyk et al., 1985; 
Ravdonikas et al., 1988; Corso et al., 1998). 
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Transferable plasmid resistance is conditioned by 
permeability of the cell membrane alteration and 
enzymatic modification of the antibiotic (Llaneza et 
al., 1985). Another described mechanism of resistance 
is FOS inactivation by opening of the bond between 
carbon and phosphorus by the C-P-lyase enzyme 
(Quinn, 1989). 
In almost all susceptible bacterial populations, FOS 
single step resistant spontaneous mutants exist with a 
high frequency (1/104 to 1/106). This resistance is due 
to the inability of FOS to penetrate the bacterial cell 
by a deficiency of transport systems, such as L-alpha-
glycerol phosphate and D-glucose-6-phosphate (Baron 
and Drugeon, 1985; Damaso et al., 1990). There is no 
evidence of cross-resistance to any other antibiotic or 
chemotherapeutic (Baron and Drugeon, 1985; Damaso 
et al., 1990; Patel et al., 1997; Gobernado, 2003; 
Gudiol, 2007; Gutiérrez et al., 2008).  
Similar to other antibiotics, shortly after the beginning 
of FOS commercialization, the concern for the 
evolution of resistance started. However, after several 
studies conducted in vitro from the '70s to the present 
using human isolated bacteria demonstrated that the 
activity against common pathogens causing infections 
in which this antibiotic is indicated has not 
significantly changed (Gobernado, 2003). 
FOS natural bacteria resistance may be due to 
transport alteration through cell wall, target alteration 
and enzymatic breakage. Acquired resistance is also 
associated with transport chromosomic alteration. 
Extrachromosomal resistance, governed by plasmids, 
also has been described. Three other different possible 
mechanisms leading to FOS resistance are the 
reduction of permeability, modification of the 
antibiotic target MurA and antibiotic modification.  
OTHER EFFECTS 
In addition to the antibacterial activity, FOS has other 
properties, such as inhibition of the adhesion of 
bacteria to epithelial cells, exopolysaccharide biofilm 
penetration, immunomodulation, phagocytosis 
promotion and protection against the nephrotoxicity 
caused by other drugs (Gobernado, 2003). 
Bacterial adhesion 
While some antibiotics at concentration under the 
MIC induce the formation of filamentous bacteria, 
favoring adherence to the urothelial cells, FOS 
reduces this phenomenon. In addition to its anti-
adhesive effect, at concentrations under the MIC, FOS 
also decreases hemolysin production and the 
hydrophobicity of E. coli, which is important in the 
prophylaxis and treatment of repeated urinary tract 
infections (Gismondo et al., 1994). 
Biofilms 
For most antibiotics it is very difficult to penetrate the 
infected exopolysaccharide biofilms that are formed 
on catheters, prosthetics, kidneys and other organ 
sites. FOS, macrolides and fluoroquinolones penetrate 
acceptably into biofilms, and the association of FOS 
with macrolides or quinolones improve the 
penetration. Furthermore, it has been shown that FOS 
produces significant alterations in cell morphology 
and in the outer membrane of P. aeruginosa 
incorporated into biofilms (Kumon et al., 1995; 
Moden et al., 2002). 
Phagocytosis 
It has been shown that FOS, at concentrations equal to 
or above the MIC, kill microorganisms located within 
phagocytes (Traub and Spohr, 1983). An increased 
neutrophil bactericidal activity has been described in 
the presence of FOS (Krause et al., 2001). Studies in 
rabbits have shown that somatic antibody titers in 
flagellar bacteria exposed to FOS- immunized animals 
were higher than those observed in animals 
immunized with bacteria not exposed to the drug 
(Viano et al., 1979). In vitro, it has been shown that 
FOS promotes migration and chemotaxis of 
polymorphonuclear phagocytes, probably by 
inhibiting respiratory enzymes, the presence of 
inactive metabolites of drugs and Adenine 
monophosphate-Guanosine monophosphate (APM-
GMP) cycle alteration (De Simone et al., 1980). 
Immunomodulation 
Numerous immunomodulatory effects of FOS have 
been reported. It has been shown to inhibit human 
lymphocyte proliferation and to decrease the release of 
IL-2, probably by blocking cell division T (Morikawa 
et al., 1993). It has been demonstrated the inhibition 
of the B cell proliferative response stimulated by S. 
aureus and the production of immunoglobulins 
without altering the expression or activation of 
antigens, such as CD25 and CD71 (Morikawa et al., 
1996). Some authors consider that FOS modifies the 
acute inflammatory response due to decreased 
synthesis of TNF-α, IL-1 α, IL-1β, the receptor 
antagonist of IL-1 and granulocyte colony stimulating 
factor (Morikawa et al., 1996; Matsumoto et al., 
1999). It has also been shown that the sensitivity of 
cells to TNF-β increases in the presence of FOS 
(Ishizaka et al., 1998). FOS has been shown to 
suppress LB4 production in neutrophils and to 
decrease the expression of IL-8 (Honda et al., 1998). 
The antiallergic property was based on its ability to 
suppress, in vitro, histamine release (Ida et al., 1987). 
Studies on a murine experimental model have 
confirmed the overall favorable immunomodulatory 
effect of FOS (Matsumoto et al., 1997). 
Protection against nephrotoxicity and ototoxicity 
Studies in animals and humans have shown that the 
concomitant use of FOS with drugs that cause 
nephrotoxicity and ototoxicity, such as cisplatin, 
cyclosporine (antitumor) (Sack et al., 1987; Suzuki et 
al., 1991; Nakamura et al., 1998), aminoglycosides, 
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vancomycin, amphotericin B and polymyxin 
(antibiotics) (Inouye et al., 1982; Morin et al.; 1984) 
protects against the undesirable effects of the other 
drugs. 
The great variety of effects, in addition to its 
antibacterial capacity, makes FOS a multifaceted drug.  
PHARMACODINAMICS 
In all species, important differences in the 
bioavailability (F) have been found after oral 
administration in relation to the various derivatives of 
FOS salts, such as disodium FOS (41-85%), calcium 
FOS (20%) and trometamol FOS (34-41%) (Segre et 
al., 1987; Patel et al., 1997). Furthermore, the IM 
administration of disodium FOS offers a more 
predictive route of dose absorption than PO 
administration. This difference may be associated with 
two facts: a) absorption from the gastrointestinal tract 
is a saturable process associated with the phosphate 
system and b) there is degradation of disodium FOS in 
acid gastric pH (Gutiérrez et al., 2008). The IM route 
is more predictive for dose absorption. Nevertheless, 
PO administration is useful for the treatment of 
intestinal infections, especially when the drug has 
poor bioavailability. 
There are differences in the bioavailability of FOS 
after IM and PO administrations, which are related 
with the type of salts used. 
PHARMACOKINETICS  
Routes of administration 
For PO administration, FOS is used as a calcium salt, 
whereas IV, IM and SC routes require the more water-
soluble disodium salt. FOS-tromethamine salt is 
highly hydro-soluble and has good bioavailability 
after oral administration (Patel et al., 1997; Popovic et 
al., 2010). 
Absorption 
After PO administration, absorption of FOS occurs 
throughout the digestive tract. However, it is higher in 
the duodenum. 
IM administration of disodium FOS shows fast and 
complete absorption. Absorption after PO 
administration has demonstrated to be variable and to 
differ between species. In mice, rats and dogs the 
range of absorption of the administered dose is of 50-
80%, whereas in humans, its absolute bioavailability is 
37-40%. 
Furthermore, differences are also observed, depending 
on whether the calcium salt or Trometamol is 
administered. Calcium salt absorption is not affected 
by the presence of food, although its bioavailability 
(F%) is lower (20-30). Tromethamine salt should be 
administered on empty stomach since the presence of 
food reduces the rate of absorption and, therefore, its 
F. However, F (40) is higher than that found with the 
calcium salt. FOS absorption occurs through a 
saturable carrier-mediated mechanism and by 
nonsaturable passive diffusion, as determined by in 
situ and in vivo experiments in rats (Ishizawa et al., 
1991).  
It is suggested that the carrier-mediated transport is 
more important for absorption, especially at 
concentrations of less than 1 mM FOS. Studies carried 
out in rats, rabbits and humans show that the 
phosphate transport might be important for the 
intestinal absorption of this antibiotic. 
Relatively small molecules which include phosphate 
within their structure may be the substrates for the 
sodium-ion-dependent transporter, enhancing the 
intestinal absorption (Tamai and Tsuji, 1996). 
Distribution 
As previously described, low protein binding (<0.5%) 
along with its low molecular weight and water 
solubility, allows good diffusion of FOS in interstitial 
fluid and tissues. 
Cerebrospinal fluid (CSF) 
No animal studies have been conducted regarding the 
concentration of FOS in CSF. In humans, it has been 
found that it readily crosses the blood brain barrier, 
diffusing to CSF (Gallego et al., 1971). Several 
studies have shown that FOS is useful in the treatment 
of meningitis caused by S. pneumoniae, 
Staphylococcus, E. coli and other Gram negative 
sensitive bacilli (Drobnic et al., 1997; Falagas et al., 
2008) when it is IV administered (1-12 g/day). FOS 
concentrations in CSF were determined to be 27.7% of 
that obtained in blood, lower than the concentrations 
found for chloramphenicol (32%), but higher than the 
values found for penicillin (7.9%) and ampicillin (15.9 
%) (Sicilia et al., 1981). Furthermore, several authors 
have found that the penetration of FOS in CSF is 
higher (300%) in inflamed meninges compared to 
non-inflamed (Boulard et al., 1983; Pfeifer et al., 
1985; Kuhnen et al., 1987). 
Interstitial fluid 
In humans, it has been demonstrated that FOS reaches 
values between 34-43% of plasma concentrations in 
interstitial fluid and cellular subcutaneous tissue in 
patients with cellulite and diabetic foot syndrome after 
an IV infusion (Legat et al., 2003). In addition, when 
IV administered, it has been demonstrated to penetrate 
the interstitial fluid of patients with burns (Koh et al., 
1986) and to reach the muscular interstitial fluid 
(Joukhadar et al. 2003). In animals, the only known 
studies were performed by Fernández Lastra et al. 
(1987) in interstitial fluid of rabbits and by Soraci et 
al. (2011c) in the fluid lining the bronchial epithelial 
of pigs. Fernandez Lastra et al. (1987) observed that 
after IV administration the half-life of FOS in 
interstitial fluid is 1.9 h, either with single or multiple 
dosages. After IM administration (15/mg/kg b.w.) of 
disodium FOS, Soraci et al. (2011a) showed that the 
drug reaches concentrations above the MIC90 of 
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pathogens such as Streptococcus, for more than 8 h in 
bronchial epithelial lining fluid. These results 
demonstrate that FOS is useful for treating diseases 
caused by extracellular microorganisms that are 
involved in swine respiratory disease. 
Placenta 
No animal studies regarding FOS passage through 
placenta have been conducted. It has been 
demonstrated in humans that after IM administration 
at a dose of 1 g,  FOS crosses the placental tissue, and 
reaches fetal maternal blood at ratios of 0.9; 0.27 and 
0.68 at 30, 90 and 120 minutes (Ferreres et al., 1977). 
Although it is apparent that the drug is safe to be 
administered during pregnancy, trometamol FOS has 
not been approved in all European countries for it use 
in pregnant women (Raz, 2012). Studies in animals 
have not shown trometamol FOS teratogenicity 
(Ferreres et al., 1977). In contrast to prolonged 
therapy the administration as a single dose in 
pregnancy reduces the risk to the fetus. However, it is 
recommended to be used in pregnancy only in cases 
where favorable risk/benefit is deemed. 
Aqueous and vitreous humor 
Most studies were performed in humans (Radda et al., 
1985; Adenis et al., 1987; Robert and Tassy, 2000). 
Only a pilot study conducted in rabbits (Adenis et al., 
1987) is available. In all cases, it was found that FOS 
reaches concentrations which are enough to inhibit 
most pathogens that cause endophthalmitis after IV 
infusion. Its use in patients with cataracts (Forestier et 
al., 1996) has also been shown. 
Bone 
In humans it has been demonstrated that FOS 
penetrates into the cortical and cancellous bone area 
after IV administration. High concentrations have 
been found in both zones (15% of plasma 
concentration) (Sirot et al., 1983; Meissner et al., 
1989). An experimental study in rats has been 
conducted using 200 mg of FOS, SC administered, in 
patients with osteomyelitis caused by Pseudomonas 
aeruginosa. This study concludes that FOS reaches 
good concentrations in bone and that concentrations 
are higher in infected bones of rats with chronic 
osteomyelitis (Fe Marques, 1994). 
Colostrum and milk 
A small proportion of FOS is eliminated by milk and 
colostrum. Fernandez Paggi et al. (2010) studied the 
distribution of disodium FOS in sow colostrum after 
the IM administration of 15 mg/kg b.w. in pigs during 
the peri-partum. FOS distribution in breast fluid is low 
and of short-term (8 h). Therefore, it could be 
administered to the sow during lactation without side 
effects in the piglets. 
Metabolism and Excretion  
FOS has no metabolic transformation (Roussos et al, 
2009). It is excreted in urine in active form, mainly by 
glomerular filtration (10% to 60%) without tubular 
secretion or reabsorption. Thus, its renal clearance is 
similar to creatinine (Eardley et al., 2006). Although, 
the excreted amount depends mainly on the 
administration form, when parenteral administration is 
employed 85 to 95% of the dose is excreted in urine 
reaching urinary concentrations in the order of 1000 to 
3000 mcg/mL (Roussos et al., 2009). Its high 
concentration in urine is maintained for at least 36 h. 
When orally administered, one third of the absorbed 
amount is excreted in urine and the remaining amount 
is eliminated in feces. 
When trometamol salt is parenterally or orally 
administered, it shows some biliary unmetabolized 
elimination (20%) and is actively reabsorbed back to 
the intestine. This enterohepatic circulation explains 
the appearance of a secondary serum peak (Segre et 
al., 1987).  
In renal failure, when the glomerular filtration rate is 
between 20-40 mL/min, it is advisable to administer 
75% of the normal dosage, and when it is less than 10 
mL/min a dosage reduction to 25 % is recommended. 
Bioavailability after parenteral administration 
corresponds to a two compartment open model. FOS 
does not bind to plasma proteins and, therefore, it 
becomes available as a fully active molecule. 
Pharmacokinetic (PK) profiles of the various 
derivatives of FOS have been described in humans 
(Kirby, 1977; Segre et al., 1987; Vargas et al., 1987), 
chickens (Aramayona et al., 1997; Soraci et al., 
2011b), rabbits (Fernández Lastra et al., 1987), cows 
(Sumano et al., 2007), dogs (Gutiérrez et al., 2008), 
horses (Zozaya et al., 2008) and weaning piglets 
(Soraci et al., 2011a). 
FOS pharmacokinetics in broiler chickens: 
Three FOS pharmacokinetic studies have been 
conducted in broiler chickens (Aramayona et al., 
1997, Gutiérrez et al., 2010; Soraci et al., 2011b). 
Aramayona et al. (1997) studied the pharmacokinetics 
of FOS in chickens after a single IV dose (10 mg/kg 
b.w.). Gutiérrez et al. (2010) studied the kinetics of 
FOS after IV administration (10, 20, 40 and 80 mg/kg 
b.w.) and PO administration (10, 20, 40 and 80 mg/kg 
b.w.). Soraci et al. (2011b) studied the kinetics of 
disodium FOS after IV (40 mg/kg b.w.) and IM (10 
mg/kg b.w.) administration and calcium FOS after PO 
administration (40 mg/kg b.w.). The authors found an 
increased bioavailability of FOS when administered 
IM (82%) compared to PO administration (39.3%). 
The volume of distribution determined by Soraci et al. 
(2011b) for FOS IV administration (231 mL / kg), is 
comparable to that found by Aramayona et al. (1997) 
(575 mL / kg) and by Gutiérrez et al. (2010) (250-220 
mL/kg). The elimination half-life of FOS after IV 
bolus administration (1.4 h; Soraci et al., 2011b, 1.8 h, 
Aramayona et al., 1997) is similar to that observed 
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after PO (1.3 h) and IM (1.1 h) administration. The 
clearance is comparable to the percentage of 
glomerular filtration rate (2.1 ml. min-1.kg
-1
) (Soraci 
et al., 2011b) and similar to that reported by 
Aramayona et al. (1997) (2.65 to 3.69 ml. min-1.kg
-1
). 
FOS pharmacokinetics in rabbits: 
There are few pharmacokinetic studies conducted in 
rabbits. In 1978, Yaginuma et al., studied the 
pharmacokinetics of IV sodium salt preparation of 
FOS in this species. In 1986, Fernandez Lastra et al. 
studied the linearity of the pharmacokinetics of FOS 
in serum and interstitial tissue fluid in rabbits, after 
administration of doses of 20, 30 and 60 mg/kg b.w. of 
the antibiotic by SC implantation of spiral steel cages. 
The elimination half-lives of FOS ranged between 
1.16 and 1.57 h. In 1987, Fernández Lastra et al., 
studied FOS levels in serum and tissue interstitial fluid 
in a multiple dosage regimen in rabbits, after the 
administration of a single dose of 60 mg/kg b.w. and 
during a multiple dosage regimen of 60 mg/kg/6h over 
three days. The elimination half-life of the drug from 
the systemic circulation after a single dose had a value 
of 1.6 h, and was not significantly different from the 
value found for the same parameter in the multiple 
dosage regimens. 
FOS pharmacokinetics in cattle: 
There is only one pharmacokinetic study of FOS in 
cattle. It was performed in 2007 by Sumano et al. 
They have studied the IV and IM pharmacokinetics of 
a single-daily dose of disodium FOS (20 mg/kg/day), 
administered for 3 days. The calculated concentrations 
at time zero and maximum serum concentrations were 
34.42 and 10.18 µg/mL (Tmax: 2.98 h), respectively. 
The elimination half-life of the drug remained 
unchanged during the 3 days (= 1.33 +/- 0.3 h for the 
IV route and = 2.17 +/- 0.4 h for the IM route). 
Apparent volumes of distribution suggest moderated 
distribution out of the central compartment (V (darea) = 
673 mL +/- 27 mL / kg and V (dss) = 483 +/- 11 
mL/kg). Bioavailability after IM administration was 
74.52%. 
FOS pharmacokinetics in dogs: 
In 1978, Yaginuma et al., studied the 
pharmacokinetics of an IV preparation of disodium 
FOS salt in dogs. Gutiérrez et al. (2008) also studied 
FOS pharmacokinetics in mongrel dogs. Nevertheless, 
they studied the variables after the administration of 
buffered disodium FOS by IV, IM, SC and PO routes 
at 40 and 80 mg/kg/day for three days. A non-
accumulative kinetic behavior was observed after 
three days with both doses and most pharmacokinetic 
variables remaining unaltered. The authors concluded 
that useful plasma concentrations can only be 
achieved after the SC injection of 80 mg/kg b.w. every 
12h, having a Cmax=18.96+/-0.3 µg/mL; a 
T1/2β=2.09+/-0.06 µg/mL and a bioavailability of 84-
85%.  
FOS pharmacokinetics in horses: 
In 2008, Zozaya et al. studied FOS pharmacokinetic 
parameters in horses after the administration of 
disodium FOS at 10 mg/kg b.w. and 20 mg/kg b.w. by 
IV, IM and SC routes. Bioavailability after the SC 
administration was 84 and 86% for the 10 mg/kg b.w. 
and the 20 mg/kg b.w. dose, respectively. It was 
concluded that clinically effective plasma 
concentrations might be obtained for up to 10 h 
administering 20 mg/kg b.w. SC.  
FOS pharmacokinetics in pigs: 
At present the only documented clinical experience of 
the use of FOS in pigs are the studies of Soraci et al. 
(2011a) and Pérez et al. (2012b). Soraci et al. (2011a) 
studied the pharmacokinetics and the bioavailability of 
disodium FOS in post-weaning piglets after IV and IM 
administration of 15 mg/kg b.w. After IV 
administration, the area under the FOS 
concentration:time curve in plasma was AUC(0-12) of 
120.00 ± 23.12 μg h/mL and the volume of 
distribution (Vd) of 273.00 ± 40.70 ml/kg.  
Plasma clearance was of 131.50 ± 30.07 ml/kg/h and a 
T1/2 of 1.54 ± 0.40 h. Peak serum concentration (Cmax), 
Tmax, AUC(0-12) and bioavailability for the IM 
administration were 43.00 ± 4.10 μg/ml, 0.75 ± 0.00 h, 
99.00 ± 0.70 μg h/ml and 85.5 ± 9.90%, respectively. 
Pérez et al. (2012b) studied the pharmacokinetics and 
the bioavailability of calcium FOS in post-weaning 
piglets after PO administration of 30 mg/kg b.w. The 
T1/2 was of 1.80 ± 0.89 h. Cmax, Tmax and 
bioavailability were 3.60 ± 0.96 µg/mL, 3.00 ± 0.00 h 
and 20.0 ± 1.85 %, respectively. The area under the 
FOS concentration:time curve in plasma AUC(0-∞) 
was 45.48 ± 9.20 µg h/mL. Table 3 shows a summary 
of the pharmacokinetics parameters of FOS in animal 
species. For PO administration, FOS is used as 
calcium and tromethamine salts, whereas for IV, IM 
and SC administrations FOS is used as the more 
water-soluble disodium salt. After PO administration, 
absorption occurs throughout the digestive tract. 
Disodium salt presents a fast and complete absorption 
(IM), which occurs through both a saturable carrier-
mediated mechanism and a nonsaturable passive 
diffusion process.  
Low protein binding, along with its low molecular 
weight and water solubility, allow good diffusion into 
interstitial fluid and tissues. It has no metabolic 
transformation. Therefore, it is excreted in urine in 
active form by glomerular filtration. PK profiles of the 
various derivates of FOS have been described in 
humans, chickens, rabbits, cows, dogs, horses and 
weaning piglets with the differences and similarities 
mentioned above. 
 
http://www.openveterinaryjournal.com 
D.S. Pérez et al. Open Veterinary Journal, (2014), Vol. 4(1): 26-43 
________________________________________________________________________________________________________ 
 
34 
Table 3. Fosfomycin pharmacokinetics parameters in animals 
 
SPECIES BROILER CHICKENS PIGS CATTLE 
    
AUTHOR 
Aramayona et al. 
(1997) 
Soraci et al. (2011b) 
Soraci et al. 
(2011a) 
Pérez et al. 
(2012b) 
Sumano et al. 
(2007) 
DETERMINATION 
METHOD 
Microbiologic 
DL: 0.5 ppm 
HPLC MS/MS 
DL: 0.1 ppm 
HPLC MS/MS 
DL: 0.1 ppm 
HPLC MS/MS 
DL: 0.1 ppm 
Microbiologic 
DL: 0.4 ppm 
FOS 
FORMULATION 
Disodium 
Disodium (IV, IM) and 
Calcium (PO) 
Disodium Calcium Disodium 
ADMINISTRATION 
ROUTE 
IV IV IM PO IV IM PO IV IM 
DOSE (mg/kg) - 40 40 10 15 15 30 20 20 
F (%) - - 39.3 81.75 - 85.50 20.00 - 74.52 
AUC (µg.h/mL) - 318 125.00 65.10 120 99.00 45.48 78.35 56.49 
Cmax (µg/mL) - - 29.79 20.70 - 43.00 3.60 - 10.18 
Tmax (h) - - 2.00 0.80 - 0.75 3.00 - 2.98 
T1/2 1.86 1.39 - - 1.54 - 1.80 2.50 2.17 
Vd (mL/kg) 575 231 - - 273 - - 483 - 
Cl (mL/kg/h) 3.12 115 - - 131.5 - - 11.20 - 
 
Table 3. Fosfomycin pharmacokinetics parameters in animals. Cont. 
 
SPECIES DOGS HORSES 
   
AUTHOR Gutiérrez et al. (2008) Zozaya et al. (2008) 
DETERMINATION 
METHOD 
Microbiologic 
DL: 0.4 ppm 
Microbiologic 
DL: 1.05 ppm 
FOS 
FORMULATION 
Disodium Disodium 
ADMINISTRATION 
ROUTE 
IV PO IM SC IV IM SC 
DOSE (mg/kg) 40 80 40 80 40 80 40 80 10 20 10 20 10 20 
F (%) - - 30 29 41 43 84 85 - - 38.00 58.00 84.00 86.00 
AUC (µg.h/mL) 92.54 176.26 22.50 48.72 36.41 82.12 78.25 143.14 307 410 115.00 224.00 249.00 
315.0
0 
Cmax (µg/mL) - - 5.20 10.84 9.61 21.71 9.46 13.96 - - 24.00 46.00 55.00 72.00 
Tmax (h) - - 2.04 1.75 1.08 1.19 2.63 2.51 - - 2.37 2.46 3.32 3.24 
T1/2 1.28 1.30 2.18 2.18 1.54 1.55 2.06 2.09 1.33 1.34 1.54 1.57 3.43 3.46 
Vd (mL/kg) 690 700 - - - - - - 215 220 - - - - 
Cl (mL/kg/h) 14.20 14.90 - - - - - - 16.00 24.00 - - - - 
http://www.openveterinaryjournal.com 
D.S. Pérez et al. Open Veterinary Journal, (2014), Vol. 4(1): 26-43 
________________________________________________________________________________________________________ 
 
35 
Treatment protocols for different species 
It is important to note that FOS can be used both 
therapeutically and prophylactically and different 
protocols of use have been suggested in several 
species. 
Broiler chickens:  
Aramayona et al. (1997) suggest that PO 
administration of FOS in drinking water at a dose of 
150 pg/mL for 5 consecutive days provides potentially 
therapeutic concentrations of the drug in chickens. 
Gutiérrez et al. (2010) suggest that useful serum 
concentrations of disodium FOS to treat outbreaks of 
susceptible E. coli require an initial loading dose of 40 
mg/kg b.w., followed by an ad libitum medication of 
40 mg/kg b.w. 8 h later (80 mg/kg per d). Soraci et al. 
(2011b) concluded that effective plasma 
concentrations of FOS for sensitive bacteria can be 
obtained following PO and IM administration. They 
suggest a useful dose of 10 mg/kg b.w. of disodium 
FOS by IM administration. After PO administration of 
calcium FOS at a dose of 40 mg/kg b.w. and an IM 
dose of disodium FOS at 10 mg/kg b.w., authors 
consider that there is an insufficient therapeutic 
efficacy in vivo in a single dose at an interval of 24 
hrs. 
Rabbits:  
Fernandez Lastra (1986, 1987) has found good results 
using doses between 20-60 mg/kg b.w, after SC 
administration (single and multiple dose dosage). 
Cattle:  
Sumano et al. (2007) suggest that clinically effective 
plasma concentrations of disodium FOS could be 
obtained for up to 8 h following IV administration and 
for approximately 10 h after IM injection of 20 mg/kg 
b.w., for susceptible bacteria. In addition to residue 
studies in milk and edible tissues, a series of clinical 
assessments, using FOS at 20 mg/kg b.w., are 
warranted before this antibacterial drug can be 
considered for use in cattle. 
Dogs:  
Gutiérrez et al. (2008) concluded that useful plasma 
concentrations can only be achieved after the SC 
injection of 80 mg/kg every 12h. 
Horses:  
Zozaya et al. (2008) determined that clinically 
effective plasma concentrations might be obtained for 
up to 10 h administering 20 mg/kg b.w. of disodium 
FOS, SC administered.  
Pigs:  
Soraci et al. (2011a) conclude that effective plasma 
concentrations of disodium FOS for sensitive bacteria 
of piglets can be obtained following IV and IM 
administration of 15 mg/kg b.w. Pérez et al. (2012b), 
determined that effective plasma concentrations of 
calcium FOS for sensitive bacteria can be obtained 
following PO administration of 30 mg/kg b.w. 
Chickens:  
150 pg/mL for 5 consecutive days (drinking water); 
initial loading dose of 40 mg/kg b.w., followed by an 
ad libitum medication of 40 mg/kg b.w. 8 h later (80 
mg/kg per d); IM (10 mg/kg b.w.), PO (40 mg/kg 
b.w).  
Rabbits:  
20-60 mg /kg b.w, SC. Cattle: 20 mg/kg b.w., IM. 
Dogs: 80 mg/kg every 12h, SC. Horses: 20 mg/kg 
b.w., SC. Pigs: 15 mg/kg b.w., IM; 30 mg/kg b.w., 
PO. 
Pharmacoeconomics 
Several studies suggest that a single dose of FOS is 
cost effective compared to other antibiotics for the 
treatment of similar infections. However, cost may be 
increased with repeated dosing (Shrestha and 
Tomford, 2001; Pullukcu et al., 2007; Popovic et al., 
2010). 
FOS is cost effective. 
Clinical use 
Although the Food and Drug Administration (FDA) 
has only approved the use of FOS for the treatment of 
infectious cystitis, it has been used to treat a broad 
variety of bacterial infections in humans, such as 
localized peritonitis, brain abscesses caused by 
Staphylococcus spp., Streptococcus spp. and E. coli 
(Sauermann et al., 2005), severe soft tissue infections 
caused by S. aureus and S. epidermidis and other 
conditions (Krause et al., 2001; Joukhadar et al., 
2003).  
In veterinary medicine, FOS is an antibiotic widely 
used in farms in Argentina, Brazil and Central 
America, being mainly prescribed in the treatment of 
infectious diseases of broiler chickens and pigs. Other 
antibiotics used for this purpose in poultry and pig 
production are chlortetracycline, oxytetracycline, 
tiamulin, tylosin, tilmicosin, enrofloxacin, sulfadiazine 
and penicillin, which are more used than FOS in other 
countries. In broilers, FOS has been used to treat E. 
coli and Salmonella spp. infections (Fernández et al., 
1998, 2001, 2002). Particularly in piglets, FOS is 
indicated to treat a wide variety of bacterial infections 
(Haemophilus parasuis, Streptococcus suis, 
Pasteurella multocida, Bordetella brochiseptica, 
Staphylococcus hyicus, Escherichia coli), associated 
with stress and/or to different viral diseases 
(Martineau, 1997). 
The use of FOS in dogs has only been suggested based 
on its low toxicity and potential efficacy (Pickrell et 
al., 1993; Gutiérrez et al., 2008). Presently, 
documented clinical experience of the use of FOS in 
horses (Zozaya et al., 2008) and cattle (Sumano et al., 
2007) is not available. 
FOS has been used to treat a broad variety of bacterial 
infections in humans. In veterinary medicine, it is 
widely used in farms in Argentina, Brazil and Central 
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America, being mainly prescribed in the treatment of 
infectious diseases of broiler chickens and pigs.   
Toxicity and side effects 
The low toxicity and potential efficacy of FOS are the 
main factors that contribute to its use in humans and 
animals (Gallego et al., 1974). Side effects are rare 
and not serious. LD50 in mice (intraperitoneally) is 4 
g/kg for the sodium salt and 20 g/kg for calcium FOS 
(Gallego et al., 1971). In humans, it can occasionally 
produce loose stools, diarrhea, nausea and vomiting 
when administered PO. The administration of 2 g per 
day divided into 4 doses for 28 days in dogs only 
caused intestinal disbacteriosis, fully recovered within 
two weeks of completion of treatment (Damaso et al., 
1990). It has also been described eosinophilia, 
thrombocytosis and discrete transaminase elevations. 
IV infusion may promote the development of 
hypernatremia or hypokalemia (Baron and Drugeon, 
1985). Allergies, anaphylaxis or severe 
hypersensitivity have not been recorded. A few cases 
of slight rash or hives which usually did not force 
discontinuing the treatment have been reported 
(Damaso et al., 1990). Its lack of teratogenic action 
for rabbit and mouse, lead to consideration that FOS a 
safe drug to be administered during infancy and, 
probably, during pregnancy (Prieto, 1986). Parenteral 
administration is painful. Thus, the solution is 
prepared with lidocaine. In humans, induration at the 
injection site and IV phlebitis have been described. 
FOS has low toxicity and side effects are rare and not 
serious. 
Intracellular penetration 
FOS penetration is demonstrated in phagocytic cells, 
where high concentrations are reached, presenting an 
intracellular activity close to that of rifampicin (Baron 
and Drugeon, 1985; Trautmann et al., 1992). Pérez et 
al. (2012a) studied FOS concentrations in respiratory 
cells (HEP-2). Intracellular concentrations of FOS 
were analyzed by HPLC MS/MS. Two formulations 
of FOS were assayed (disodium FOS: 280 and 130 
μg/mL; calcium FOS: 130 μg/mL). Concentrations in 
HEp-2 cells incubated with 280μg/mL of disodium 
FOS ranged from 0.74 to 2.79μg/mL (Tmax: 12 h). 
When incubated with the same formulation of FOS at 
a concentration of 130 μg/mL, intracellular 
concentrations ranged between 0.31 and 1.60 μg/mL 
(Tmax: 12 h). Calcium FOS reached intracellular 
concentrations that varied between 0.46 and 1.11 
μg/mL (Tmax: 8 h). FOS concentrations exceeded the 
MIC90 for the most important pathogens in swine 
respiratory infections (Streptococcus spp.; 
0.25μg/mL). Therefore, it is apparent that FOS is an 
alternative drug for the treatment of intracellular 
respiratory infections in pigs. 
Martínez et al. (2011) have studied FOS penetration in 
cell culture lines and evaluated the interactive effect of 
deoxinivalenol (DON) on the penetration of the 
antibiotic. The results showed that intracellular 
antibiotic concentrations in HEp-2 cells incubated 
with 130 ppm of calcium FOS oscillated between 0.4 
and 1.12 mg/ml with a Tmax of 8 h. When HEp-2 cells 
were incubated with FOS and DON, a significant 
variation was not observed in the cellular penetration 
of the antibiotic, according to the Cmax (1.10 ppm) and 
Tmax (12 h). Authors concluded that the presence of 
the mycotoxin would not alter the cellular distribution 
of FOS in pigs. 
Pérez et al. (2013a) studied the penetration of FOS in 
an in vitro model of intestinal cells (IPEC-J2 cells). 
Cells cultures were subjected to 580 µg/mL of calcium 
FOS. Intracellular concentrations of the antibiotic 
were analyzed by HPLC MS/MS and they ranged 
from 23.48 to 45.81 µg/mL (Tmax: 4 h). FOS 
concentrations exceeded the MIC90 for the most 
important pathogens in swine intestinal infections 
(Escherichia coli: 0.50 µg/mL, Salmonella enterica 
subsp. enterica: 4 µg/mL). Therefore, it is apparent 
that FOS is an alternative choice for the treatment of 
intestinal infections in pigs. 
Martínez et al. (2012) cultured intestinal explants 
from the jejunum of pigs and applied the model to 
study the intracellular penetration of FOS in the 
presence or absence of DON. The results suggest that 
there was no statistically significant difference in the 
intracellular concentration of FOS between explants 
incubated with 580 ppm FOS and explants incubated 
with 580 ppm FOS and 1ppm DON. The Cmax was 12 
ppm and the Tmax was 2 h. Only 2 % of the antibiotic 
is intracellularly accumulated and the intracellular 
concentration of FOS is not affected by the presence 
of non-toxic concentrations of DON. 
FOS penetration is demonstrated in phagocytic, 
respiratory and intestinal cells, where adequate 
concentrations are reached. 
FOS determination in biological matrices 
There are only a few methods for FOS detection in 
biological matrices (Pianetti 1997; Loste et al., 
2002; Petsch et al., 2005; Gutiérrez et al., 2008; 
Zozaya et al., 2008).  
In 1980, FOS dosage by a stationary phase of 
octadecylsilane chemically bonded with the formation 
of an ion pair, or using an ion-exchange column 
connected to a detector anionic by flame photometry 
selective phosphorus atom were proposed (Chester et 
al., 1981). Its low molecular weight, low UV 
absorption and lack of fluorescence, are characteristics 
that hinder its analysis (Yu-Ling et al., 1999). For this 
reason, for gas chromatography analysis FOS should 
be derivatized, meaning that a chemical modification 
must be introduced into FOS to facilitate its analysis 
and detection (Loste et al., 2002). However, the 
limitation of this method is that is time consuming due 
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to derivatization steps. Other studies determine FOS 
by microbiological methods (Sumano et al., 2007) or 
by capillary electrophoresis (Petsch et al., 2005). 
Currently, high resolution liquid chromatography 
coupled to a mass spectrometer (HPLC MS/MS) is the 
method of choice for xenobiotics determination. Its 
use has been described for FOS determination in 
serum of humans (Li, 2007), chickens (Dieguez et al., 
2011; Soraci et al., 2011b) and piglets (Soraci et al., 
2011a; Pérez et al., 2012b) and in broiler chicken and 
pig tissues (Pérez et al., 2011, 2013b).  
Compared with the methods mentioned above, HPLC 
MS/MS is the method of choice to perform these 
determinations due to its specificity and the lack of 
need for derivatization. 
There are only a few methodologies for FOS detection 
in biological matrices. HPLC MS/MS is the method of 
choice for FOS determination due to its specificity and 
the lack of need for derivatization. 
FOS concentrations in different tissues  
As mentioned above, it has been shown that FOS has a 
very low protein binding, and this, along with its low 
molecular weight and water solubility, allow good 
tissue diffusion. 
FOS concentrations in animal tissues for human 
consumption 
FOS tissue residues studies have been conducted in 
broiler chickens and swines. Aramayona et al. (1997), 
determined, by microbiological assay, FOS residual 
concentrations in various tissues (kidney, liver, lung, 
muscle, heart, fat, gizzard) after chronic 
administration of the antibiotic in drinking water (150 
micrograms/mL, during 5 days). At day 6 of the assay, 
FOS was detected in all tissues, except in muscle, in 
concentrations between 0.63 mg/g in fat to 13.48 mg/g 
in kidney. 24 hrs later, concentrations were below the 
detection limit of the method. Mestorino et al. (2011) 
studied the residual profile of FOS in broiler chickens 
after PO administration of calcium FOS (10 mg/kg 
b.w.) in water, for 5 days.  
FOS concentrations were determined in muscle, 
skin/fat, liver, kidney and feathers, by microbiological 
assay. To determine FOS withdrawal time (WDT), 
Mestorino et al. (2011) have used the only MRL 
established by The Japan Food Chemical Research 
Foundation for bovine tissues (0.5 ppm).  
In muscle, FOS concentrations were below the method 
detection limit (0.0625 mg/g) from the fourth day of 
discontinuation of FOS administration. In skin/fat 
concentrations of 0.337 mg/g were obtained the first 
day after administration, and from the second day, 
values were below the detection limit. The highest 
concentrations were found in liver, falling below the 
detection limit, from the fourth day after ending the 
treatment. In kidney, they found concentrations of 
0.447 mg/g, which, on the second day, were below the 
detection limit. WDT for FOS in muscle and liver 
were determined by 1.4 WT program, being 7 and 5 
days, respectively (Mestorino et al., 2011). Pérez et al. 
(2011) determined FOS residual concentrations by 
HPLC MS/MS and WDT in muscle (pectoral, thigh 
and injection site), liver and kidney of broiler chickens 
after PO and IM administrations.  
In this study, the WDTs of FOS were determined 
considering also the Maximum Residue Limit (MRL) 
defined by Japan. Concentrations of FOS in muscle, 
liver and kidneys were always below the MRL. In 
addition, after 72 h of FOS food withdrawal and IM 
administration, the values of the residual 
concentrations of the drug in tissues were below the 
0.1 mg/g detection limit. FOS WDT in muscle was 1-2 
days, being of 1.12 days for calcium FOS (PO assay) 
and 1.72 days for disodium salt (IM assay). 
Differences between FOS WDTs in muscle may be 
due to the distinct formulations and routes of 
administration.  
The same applies to WDTs in liver and kidney, which 
are also longer after FOS PO calcium food 
consumption (1.27 vs. 0.42 days and 2.55 vs. 0.92 
days, respectively). Authors conclude that a WDT of 2 
days after IM administration and of 3 days after PO 
administration could be assigned as a precautionary 
principle for public health, without a significant 
economic impact for broiler producers. 
Perez et al. (2013b) have also determined FOS 
residual concentrations and WDT in swine muscle, 
liver, kidney and skin/fat, after PO and IM 
administration. In both assays, FOS concentrations in 
all the matrices were below the MRL after 48 h of 
FOS food withdrawal and IM administration. After 72 
h, the values of the residual concentrations of the drug 
in the analyzed tissues were below the 0.1 mg/mL 
detection limit of the method. FOS WDT in muscle 
was 2-3 days, being of 2.78 days for calcium FOS (PO 
assay) and 1.48 days for disodium salt (IM assay). 
WDTs in liver and kidney are longer for FOS after PO 
administration of calcium FOS in food (2.69 vs. 1.73 
days and 2.95 vs. 1.38 days, respectively) (Pérez et al., 
2013b). No significant differences were found 
between the WDTs for skin-fat after the PO assay (0.9 
days) and the IM assay (1.27). A WDT of 3 days for 
the PO administration and of 2 days for the IM 
administration were assigned. 
FOS tissue residue studies have been conducted in 
broiler chickens and swines for WDT determination, 
after PO and IM administration of calcium and 
disodium FOS, respectively (Pérez et al., 2011, 
2013b). For both species a WDT of 3 days after PO 
administration and of 2 days after IM administration 
could be assigned as a precautionary principle for 
public health, without a significant economic impact 
for producers. 
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Conclusion 
FOS is a good antibiotic, with a fast effect, good 
tolerance and physicochemical and pharmacokinetic 
characteristics that allow its enteral and parenteral 
administration. Its pharmacokinetics has been studied 
in most domestic animal species. However, it is not 
widely used in veterinary medicine, being almost 
limited to intensive production of broiler chickens and 
pigs. The low toxicity and potential efficacy of FOS 
are the main factors that contribute to its use in 
humans and animals. This, together with the additional 
properties of the drug (inhibition of bacterial adhesion 
to epithelial cells, penetration in exopolysaccharide 
biofilm, immunomodulatory effect, promotion of the 
phagocytosis and protection against the nephrotoxicity 
caused by other drugs, intracellular penetration and 
diffusion into bacteria biophases), gives an extra value 
to FOS and make it a good option in the treatment of 
infectious diseases caused by sensitive organisms. 
___________________________________________ 
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